Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER TSUNG-JER CHEN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1467865527
CMS profile
404891
Location
STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$178.72

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $178.72 8

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER TSUNG-JER CHEN

NPI 1467865527 · CMS profile ID 404891

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467865527?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER TSUNG-JER CHEN, NPI 1467865527, CMS profile ID 404891. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467865527?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHRISTOPHER TSUNG-JER CHEN, NPI 1467865527, CMS profile ID 404891. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467865527?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHRISTOPHER TSUNG-JER CHEN, NPI 1467865527, CMS profile ID 404891, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1467865527?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $178.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Karyopharm Therapeutics Inc. $23.7210/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946514419 CMS
Pharmacyclics LLC, an AbbVie Company $26.2610/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890337999 CMS
Janssen Biotech, Inc. $32.3707/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885569329 CMS
AstraZeneca Pharmaceuticals LP $23.3206/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915205397 CMS
Karyopharm Therapeutics Inc. $23.3306/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946514413 CMS
Janssen Biotech, Inc. $16.8504/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885569325 CMS
Janssen Biotech, Inc. $18.3704/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885569333 CMS
E.R. Squibb & Sons, L.L.C. $14.5002/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932664011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,006.25 1
PY2021 $145.90 3
PY2022 $178.72 8
PY2023 $62.47 1
PY2024 $1,635.00 1
PY2025 $62.76 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $707,691.77 495
PY2024 Principal investigator $393,389.61 73
PY2023 Principal investigator $147,275.13 49
PY2022 Principal investigator $600,857.90 56
PY2021 Principal investigator $52,306.74 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $1,206.39 12/10/2024 Non-covered Recipient Entity
STANFORD UNIVERSITY
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1133441493
Principal investigator 1 Genentech, Inc. $1,548.19 12/10/2024 Non-covered Recipient Entity
STANFORD UNIVERSITY
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1133441501
Principal investigator 1 Genentech, Inc. $1,343.74 12/10/2024 Non-covered Recipient Entity
STANFORD UNIVERSITY
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1133441505
Principal investigator 1 Genentech, Inc. $2,276.31 12/10/2024 Non-covered Recipient Entity
STANFORD UNIVERSITY
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1133441509
Principal investigator 1 ADC Therapeutics America, Inc. $2,171.00 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521718
Principal investigator 1 ADC Therapeutics America, Inc. $3,018.44 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521720
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521722
Principal investigator 1 ADC Therapeutics America, Inc. $4,948.32 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521724
Principal investigator 1 ADC Therapeutics America, Inc. $2,629.00 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521726
Principal investigator 1 ADC Therapeutics America, Inc. $5,285.08 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521728
Principal investigator 1 ADC Therapeutics America, Inc. $3,710.00 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521730
Principal investigator 1 ADC Therapeutics America, Inc. $3,771.00 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521732
Principal investigator 1 ADC Therapeutics America, Inc. $2,202.00 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521734
Principal investigator 1 ADC Therapeutics America, Inc. $539.44 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521736
Principal investigator 1 ADC Therapeutics America, Inc. $2,256.00 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521738
Principal investigator 1 ADC Therapeutics America, Inc. $1,713.00 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521740
Principal investigator 1 ADC Therapeutics America, Inc. $3,668.60 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521742
Principal investigator 1 ADC Therapeutics America, Inc. $2,629.04 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521744
Principal investigator 1 ADC Therapeutics America, Inc. $2,201.66 12/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521746
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $693.40 12/02/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1125499910
Principal investigator 1 Genentech, Inc. $44,894.95 10/15/2024 Non-covered Recipient Entity
STANFORD UNIVERSITY
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1133441474
Principal investigator 1 Genentech, Inc. $14,400.00 10/15/2024 Non-covered Recipient Entity
STANFORD UNIVERSITY
Ph 1a 1b of aCCR8 in Solid Tumors No dispute reported 06/30/2026 1133441477
Principal investigator 1 Genentech, Inc. $1,184.00 10/02/2024 Non-covered Recipient Entity
STANFORD UNIVERSITY
Ph 1 RO7568589 in Pancreas Colon and Lung Cancer No dispute reported 06/30/2026 1133441465
Principal investigator 1 ADC Therapeutics America, Inc. $448.00 09/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521702
Principal investigator 1 ADC Therapeutics America, Inc. $640.00 09/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521704
Principal investigator 1 ADC Therapeutics America, Inc. $128.00 09/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521706
Principal investigator 1 ADC Therapeutics America, Inc. $1,280.00 09/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521708
Principal investigator 1 ADC Therapeutics America, Inc. $3,840.00 09/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521710
Principal investigator 1 ADC Therapeutics America, Inc. $512.00 09/06/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521712
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,376.00 09/04/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1125478220
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97,177.26 09/04/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1125478222
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,301.12 09/04/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1125478224
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30,272.00 09/04/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1125478226
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,280.00 09/04/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1125478228
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,824.92 09/04/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1125478230
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,884.98 07/19/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1125478106
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,896.00 07/16/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior University
Brightline-2 PhIIa/IIb Brigimadlin mono in MDM2 amp tumors No dispute reported 06/30/2026 1101073293
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,769.60 03/26/2024 Non-covered Recipient Entity
Stanford Medicine Cancer Center Blake Wilbur
Brightline-2 PhIIa/IIb Brigimadlin mono in MDM2 amp tumors No dispute reported 06/30/2026 1101069849
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $54,048.19 01/27/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior University
Brightline-2 PhIIa/IIb Brigimadlin mono in MDM2 amp tumors No dispute reported 06/30/2026 1101073291
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521426
Principal investigator 1 ADC Therapeutics America, Inc. $68.79 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521428
Principal investigator 1 ADC Therapeutics America, Inc. $4,523.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521430
Principal investigator 1 ADC Therapeutics America, Inc. $2,202.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521432
Principal investigator 1 ADC Therapeutics America, Inc. $2,256.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521434
Principal investigator 1 ADC Therapeutics America, Inc. $2,629.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521436
Principal investigator 1 ADC Therapeutics America, Inc. $537.60 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521438
Principal investigator 1 ADC Therapeutics America, Inc. $2,171.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521440
Principal investigator 1 ADC Therapeutics America, Inc. $4,186.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521442
Principal investigator 1 ADC Therapeutics America, Inc. $3,669.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521444
Principal investigator 1 ADC Therapeutics America, Inc. $113.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521446
Principal investigator 1 ADC Therapeutics America, Inc. $210.52 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521448
Principal investigator 1 ADC Therapeutics America, Inc. $88.54 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521450
Principal investigator 1 ADC Therapeutics America, Inc. $68.79 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521452
Principal investigator 1 ADC Therapeutics America, Inc. $68.79 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521454
Principal investigator 1 ADC Therapeutics America, Inc. $68.79 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521456
Principal investigator 1 ADC Therapeutics America, Inc. $68.79 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521622
Principal investigator 1 ADC Therapeutics America, Inc. $68.79 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521624
Principal investigator 1 ADC Therapeutics America, Inc. $68.79 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521626
Principal investigator 1 ADC Therapeutics America, Inc. $68.79 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521628
Principal investigator 1 ADC Therapeutics America, Inc. $3,669.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521630
Principal investigator 1 ADC Therapeutics America, Inc. $4,523.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521632
Principal investigator 1 ADC Therapeutics America, Inc. $2,256.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521634
Principal investigator 1 ADC Therapeutics America, Inc. $4,523.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521636
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521638
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521640
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521642
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521644
Principal investigator 1 ADC Therapeutics America, Inc. $2,256.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521646
Principal investigator 1 ADC Therapeutics America, Inc. $3,669.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521648
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521650
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521652
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521654
Principal investigator 1 ADC Therapeutics America, Inc. $539.00 01/19/2024 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior Unv.
ADCT-601-102 No dispute reported 06/30/2026 1126521656